Related by context. All words. (Click for frequent words.) 68 HLA DR2 68 HLA DR4 immune 68 Flu Cy 67 achieved CCyR 67 mutated KRAS 67 lymphocytosis 67 K ras mutations 66 FLT3 65 Ph + acute lymphoblastic 65 paclitaxel cisplatin 65 papillary renal cell carcinoma 65 KRAS mutations 65 underwent surgical resection 65 non mutated KRAS 65 cisplatin resistant 64 relapsed MM 64 ERBB2 64 biochemical relapse 64 underwent resection 64 KRAS wild 64 demonstrated antitumor activity 64 splenectomized 64 Ribavirin causes 64 hepatocellular carcinomas 64 mutated K ras 64 sarcomatoid 64 metastatic malignant 64 nutlin 3a 64 oblimersen 64 castrate resistant 64 bortezomib refractory 64 chlorambucil 64 epithelial tumors 63 antithymocyte globulin 63 partial remissions 63 NMIBC 63 experimental autoimmune encephalomyelitis 63 HBeAg positive patients 63 syngeneic 63 leukemia AML 63 NSCLC tumors 63 HBeAg negative patients 63 tumors GIST 63 SOD2 gene 63 recurrent glioblastoma multiforme 63 colon carcinoma 63 imatinib resistant 63 FOLFOX chemotherapy 63 thyroid carcinoma 63 refractory NSCLC 63 Gleevec resistant 63 haematologic 63 CD#c 63 KRAS mutant 63 Leydig cells 62 antiretroviral naïve 62 T#I [002] 62 xenograft models 62 colorectal carcinoma 62 orthotopic 62 KRAS mutant tumors 62 tryptase 62 MGd 62 % CI #.#-#.# [007] 62 constitutively expressed 62 KRAS mutations occur 62 progesterone receptor negative 62 transfected 62 immunostaining 62 thalidomide Thalomid 62 breast carcinoma 62 interleukin IL -# 62 essential thrombocythemia ET 62 small lymphocytic lymphoma 62 TNFalpha 62 MLH1 62 NOD SCID mice 62 K ras 62 pancreatic adenocarcinoma 62 peripheral blood mononuclear 62 TIMP 1 62 adriamycin 62 autoantibody positive 62 interferon IFN 62 mg kg dose 62 progression TTP 62 Pharmacokinetics PK 62 epithelioid 62 pT3 62 imatinib Gleevec 62 lymphocytic 62 etoposide 62 refractory chronic myeloid 62 fibrosarcoma 62 immunoreactivity 62 homozygotes 62 hypereosinophilic syndrome 62 cisplatin gemcitabine 62 Folfox 62 TOP2A 62 ara C 62 cyclophosphamide methotrexate 62 HepG2 cells 62 FOLFIRI alone 61 Myelodysplastic Syndrome MDS 61 C#Y 61 lactate dehydrogenase LDH 61 pegylated liposomal doxorubicin 61 ribavirin RBV 61 cytokeratin 61 mRNA expression 61 Diffuse Large B 61 estrogen receptor ER 61 mutant KRAS 61 CC genotype 61 dornase alfa 61 baseline LDH 61 galiximab 61 Partial Responses 61 nondiabetic patients 61 CR nPR 61 mucinous 61 hepatoma 61 HBeAg 61 alkylating agent 61 azacytidine 61 cetuximab Erbitux R 61 myelodysplastic myeloproliferative diseases 61 gastric carcinoma 61 cytogenic 61 lung adenocarcinomas 61 immunodeficient 61 bronchoalveolar lavage fluid 61 KRAS oncogene 61 mCRC patients 61 patients evaluable 61 gefitinib Iressa 61 dexamethasone Decadron 61 HER2 overexpression 61 downregulated 61 EGFR receptor 61 cellularity 61 follicular lymphomas 61 receptor tyrosine kinase inhibitor 61 HER2 expression 61 lung metastases 61 lymphoid cells 61 JAK2 V#F 61 CRu 61 selective modulator 61 acute lymphoblastic 61 Doxil ® 61 IFN gamma 61 BRAF V#E 61 EGFR mutation positive 61 lactate dehydrogenase 61 EGFR mutant 61 breast carcinomas 61 prostate carcinoma 61 pDC 61 Clusterin 61 Vidaza ® 61 monocytic 61 complete cytogenetic response 61 cells PBMC 61 pCR 61 myeloablative 61 cytoreduction 61 oral clodronate 61 retinoic acid receptor 61 retinal ischemia 61 HER2 HER2 61 metastatic GIST 61 K#R [002] 61 taxane chemotherapy 61 Platinol ® cisplatin 61 subependymal giant cell 61 tumor regressions 60 neoplastic cells 60 thrombocytopenic 60 gemcitabine carboplatin 60 Refractory Hodgkin Lymphoma 60 circadian genes 60 FOLFOX4 60 deep venous thromboses 60 induced apoptosis 60 TET2 60 CD# CD# 60 carcinoid 60 Paraplatin ® carboplatin 60 mitoxantrone chemotherapy 60 glutamic acid decarboxylase 60 ANCA associated 60 missense mutations 60 squamous cell carcinoma SCC 60 locoregional recurrence 60 lymphoid malignancies 60 gastrointestinal stromal tumors GISTs 60 Naive Patients 60 adalimumab Humira 60 systemic anaplastic large 60 bevacizumab Avastin R 60 dacarbazine DTIC 60 type KRAS 60 unresectable tumors 60 HER2 receptor 60 Hurthle cell 60 IFN alpha 60 HBsAg 60 HBeAg positive 60 CLL SLL 60 enteroviral 60 HER2/neu 60 stage IIIb IV 60 xenograft tumors 60 Leukemias 60 pegylated interferon alpha 60 AZT zidovudine Retrovir 60 ABCB1 60 paraganglioma 60 ERalpha 60 ritonavir boosted 60 hepatic metastases 60 immunocompetent 60 hepatorenal syndrome 60 AGTR1 60 Endometrial 60 invasive lobular 60 epirubicin cyclophosphamide 60 pegylated alpha interferon 60 TNF α 60 oral squamous cell 60 REYATAZ r arm 60 tumorigenicity 60 allogeneic HSCT 60 splenectomized patients 60 xenograft 60 anthracycline taxane 60 localized renal 60 AML MDS 60 pretransplant 60 Virologic 60 PDGFR 60 alkaline phosphatase ALP 60 prostate adenocarcinoma 60 humoral responses 60 achieved sustained virologic 60 adverse cytogenetics 60 dasatinib Sprycel ® 60 RRM1 60 recurrent metastatic 60 Mesenchymal 60 endocrine therapies 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 factor HGF 60 EGFR HER2 60 ALT normalization 60 bovine thrombin 60 normal karyotype 60 alefacept 60 interferon ribavirin 60 TTR gene 60 receiving VICTRELIS 60 V#F mutation 60 monocyte chemotactic protein 60 unmutated 60 pamidronate 60 FUSILEV enhances 60 neoplastic 60 seropositivity 60 4mg/kg 60 CLL cells 60 squamous histology 60 cisplatin chemotherapy 60 refractory chronic lymphocytic 60 euthyroid 60 imatinib Gleevec ® 60 docetaxel chemotherapy 60 % CI #.#-#.# [003] 60 SSc 60 lymph node metastasis 60 pathophysiological effects 60 metastatic gastric 60 estramustine 60 hypermethylated 60 chronic myeloid 60 IFN α 60 LHRH receptor positive 60 hA# 60 allogeneic bone marrow 60 gastrointestinal stromal tumor GIST 60 murine model 60 anastrazole 60 Azacitidine 60 KRAS gene 60 experimentally induced 60 Response Evaluation Criteria 60 radiation chemoradiation 59 LRAT 59 K RAS 59 busulfan 59 PC# cells 59 carcinoembryonic antigen 59 pT2 59 FOLFOX6 59 metastatic malignant melanoma 59 HLA A2 59 ERK1 2 59 kidney urologic 59 tumor xenograft models 59 variant alleles 59 detectable HCV RNA 59 cilengitide 59 pmol L 59 potently inhibited 59 tumoral 59 CD4 + CD# 59 bleomycin 59 bronchoalveolar lavage BAL 59 cytogenetic responses 59 gemcitabine cisplatin 59 Camptosar ® 59 Pegylated Interferon 59 metastatic pancreatic 59 chronic eosinophilic leukemia 59 mouse xenograft models 59 seronegative 59 EGFRvIII 59 autologous SCT 59 XL# inhibits 59 isotypes 59 systemically administered 59 prospectively stratified 59 neutrophil counts 59 rHuEPO 59 Cytotoxic T 59 ErbB2 positive 59 receptor blocker 59 exendin 4 59 genotype 1a 59 Fludarabine 59 BRAF gene mutations 59 genotypic resistance 59 distant metastasis 59 mitoxantrone plus 59 FLT3 mutations 59 GBM tumors 59 wildtype 59 achieved ACR# 59 mTOR inhibitors 59 BRAF mutations 59 receptor inhibitor 59 Immunohistochemical staining 59 rituximab refractory 59 tumor necrosis 59 somatostatin 59 hypophosphatemia 59 RECIST Response Evaluation Criteria 59 pulmonary metastases 59 trastuzumab Herceptin ® 59 daunorubicin 59 lenalidomide Revlimid 59 radiosensitivity 59 TRAIL R2 59 p# deficient 59 cytotoxic T lymphocyte 59 J. Clin 59 tumor regression 59 Serum concentrations 59 achieved sustained virological 59 bronchoalveolar lavage 59 davunetide intranasal AL 59 Solid Tumors criteria 59 overexpressing 59 -#.# log# 59 ADPKD 59 hematological relapse 59 cervical lymph nodes 59 untreated metastatic melanoma 59 mg TID 59 RECIST criteria 59 taxane therapy 59 PBMCs 59 evaluable 59 vWF 59 cancer mCRC 59 erlotinib Tarceva ® 59 sunitinib Sutent 59 metaplasia 59 atazanavir ritonavir 59 chemoresistant 59 comparator arm 59 alpha folate receptor 59 TRAIL R1 59 hematopoietic progenitors 59 immunized mice 59 HER2 amplified 59 aMCI precursor 59 IgA deficiency 59 melphalan prednisone 59 amoxicillin clavulanate 59 temozolomide TMZ 59 leukemia CLL 59 hypoxia inducible factor 59 fluvastatin 59 orthotopic model 59 μg doses 59 acute myeloid 59 anaplastic astrocytoma AA 59 histologically 59 HLA DR4 59 microvascular endothelial cells 59 GSTP1 59 undergoing hematopoietic stem 59 alkylating 59 LNCaP cells 59 refractory Hodgkin 59 IL #p# 59 EGFP 59 FUS1 59 neuroendocrine cancers 59 androgen suppression 59 multiple myeloma MM 59 CsA 59 preoperative chemotherapy 59 antiretroviral naive 59 invasive carcinomas 59 mRCC 59 inducible nitric oxide synthase 59 BRAF V#E mutation 59 metastatic colorectal 59 IL#B 59 CD3 + 59 NRTI resistance 59 ovarian carcinoma 59 gemcitabine Gemzar 59 serous ovarian cancer 59 refractory gastrointestinal stromal 59 p = NS 59 Fludara ® 59 mononuclear 59 cell acute lymphoblastic 59 CCyR 59 HER2 neu 59 erythropoietic 59 allogeneic hematopoietic stem cell 59 BARACLUDE ® 59 receiving highly emetogenic 59 cell lymphoma CTCL 59 trastuzumab Herceptin R 59 whose tumors overexpress 59 PDGFR alpha 59 T1c 59 preferentially bind 59 CR CRu 59 GHRH 59 nicardipine 59 EGFR TKI 58 complement inhibitor eculizumab 58 transgenic rats 58 liposomal doxorubicin 58 pharmacokinetic parameters 58 activating mutations 58 cytotoxin 58 trans retinoic acid 58 K#N 58 orally administered inhibitor 58 CagA 58 interferon alfa 2b 58 CHOP chemotherapy 58 IFN γ 58 flavopiridol 58 bladder carcinoma 58 anti inflammatory cytokine 58 haematopoietic 58 locoregional disease 58 pheochromocytoma 58 MSH2 58 CCR5 delta# 58 transduced 58 idiopathic membranous nephropathy 58 μmol L 58 HER2 amplification 58 plasma uric acid 58 caspofungin 58 IDH1 mutation 58 EGFR mutation 58 μg ml 58 lenalidomide Revlimid R 58 Estrogen Receptor 58 Antitumor Activity 58 WT1 58 PEG IFN 58 Introgen ADVEXIN 58 HIV coinfected 58 Wwox 58 EGFR tyrosine kinase inhibitors 58 mitoxantrone 58 hamartomas 58 nonmetastatic 58 leukocyte count 58 liver histology 58 PEGylated anti 58 deletion 5q 58 proto oncogene 58 pleomorphic 58 FOLFOX 58 ductal lobular 58 metastatic neuroendocrine tumors 58 plus dexamethasone 58 TRAIL induced apoptosis 58 del 5q 58 EGFR mutations 58 p# MAP kinase inhibitor 58 alanine aminotransferase ALT 58 BRAF mutant 58 anaplastic lymphoma kinase ALK 58 imatinib therapy 58 TERT 58 Ki# 58 low dose cytarabine 58 thymoma 58 FDG uptake 58 tipranavir ritonavir 58 de novo AML 58 autologous transplant 58 mutated KRAS gene 58 daily subcutaneous injections 58 timepoints 58 ERK signaling 58 isotype 58 ertapenem 58 weekly subcutaneous injections 58 hemagglutination inhibition HAI 58 CD# expression [002] 58 HBeAg negative 58 Chronic lymphocytic leukemia CLL 58 neurofibromas 58 ipsilateral breast 58 KRAS status 58 IFNg 58 Philadelphia Chromosome Positive 58 DAS# CRP 58 Anthracycline 58 systemic ALCL 58 receiving ISENTRESS 58 cynomolgus monkeys 58 Cell Lymphoma CTCL 58 CDK inhibitor 58 survivin expression 58 non splenectomized 58 operable breast cancer 58 FluCAM arm 58 Heterozygous 58 Th2 cytokines 58 mTOR mammalian target 58 BRCA1 BRCA2 58 hyaluronidase enzyme 58 5 FU leucovorin 58 MDA MB 58 biochemical recurrence 58 bone marrow stromal cells 58 vinca alkaloid 58 hormone receptor negative 58 insulin glulisine 58 immunohistochemical staining 58 CYT# potent vascular disrupting 58 antiangiogenic therapy 58 abacavir lamivudine 58 anthracyclines taxanes 58 virological response 58 resected pancreatic cancer 58 IU ml 58 complete cytogenetic 58 isoenzyme 58 affective psychosis 58 UGT#A# * 58 TP# mutations 58 CTL epitopes 58 abacavir Ziagen 58 CD# + [001] 58 colorectal adenoma 58 potent inducer 58 decitabine 58 MIC# [001] 58 anthracycline containing 58 anaphylactic reactions bronchospasm 58 invasive ductal 58 mg ustekinumab 58 Thal Dex 58 adipogenic 58 CD# expressing 58 selectively inhibited 58 constitutively active 58 refractory acute myeloid 58 C#BL 6 mice 58 estrogen receptor progesterone receptor 58 atypical hemolytic uremic syndrome 58 fluorouracil 58 8mg/kg 58 EBMT criteria 58 underwent liver transplantation 58 metastatic renal cell 58 CD8 + cytotoxic 58 pDCs 58 PROSTVAC VF 58 HER-2/neu 58 hematopoietic cell 58 advanced adenomas 58 Glioblastoma Multiforme 58 mutational status 58 receiving immunosuppressive therapy 58 Platelet counts 58 inactivating mutations 58 response CCyR 58 basal cell carcinoma BCC 58 rs# [004] 58 ovariectomized 58 colorectal adenocarcinoma 58 seminomas 58 idarubicin 58 immune globulin intravenous 58 idiopathic thrombocytopenic purpura 58 nM 58 CML CP 58 severe neutropenia 58 tumor histology 58 CRp 58 intravenous bolus 58 PSADT 58 subcutaneously injected 58 frameshift mutation 58 alpha2 58 alfa 2a 58 steroid refractory 58 fibrinolysis 58 ALT flares 58 antiphospholipid antibodies 58 R Saizen R 58 rituximab Rituxan 58 Glioblastoma multiforme GBM 58 Mg Uk 58 p# antigen 58 Cryptococcus neoformans 58 p# activation 58 fluoropyrimidine 58 remission CR 58 elevated LDH 58 neutropenic sepsis 58 histologic subtype 58 JAK2 enzyme 58 Corynebacterium 58 vWD 58 CD# expression [001] 58 Bezielle 58 antibody titer 58 5FU 58 CD8 T cell 58 #F FDG 58 cMET 58 dose cohort 58 heavily pretreated 58 ptau 58 lymphomas leukemias 58 overt nephropathy 58 lung metastasis 58 Peg IFN 58 invasive aspergillosis 58 supernatants 58 mesalamine granules 58 antiangiogenic agent 58 Myelodysplastic Syndrome 58 transfected cells 58 histological subtype 58 leukemia APL 58 Leydig cell 58 pancreatic endocrine 58 gastrointestinal stromal tumors GIST 58 Fibroblast 58 IGF IR 58 radiolabeled antibodies 58 recombinant erythropoietin 58 isoproterenol 58 advanced adenoma 58 seropositive patients 58 autologous transplants 58 nmol 57 heterozygotes 57 osteosarcomas 57 5 Fluorouracil 57 ischemia driven 57 Autoantibodies 57 NFkB 57 leukaemias 57 irinotecan containing 57 Her2/neu 57 thymidine 57 Xelox 57 PCNSL 57 nadolol 57 CD8 + 57 receiving VELCADE 57 PegIFN RBV 57 prior chemotherapy regimens 57 doxorubicin cyclophosphamide 57 #mg/day [002] 57 targeted antifolate 57 castration resistant 57 pharmacodynamic PD 57 radioiodine therapy 57 BRCA deficient 57 phorbol 57 clinicopathological features 57 hematopoietic cancers 57 bladder ovarian 57 steatohepatitis 57 constitutively activated 57 germline mutations 57 interferon beta 1a infertility 57 allogeneic stem cell 57 transgene expression 57 deacetylation 57 Immunohistochemical analysis 57 dasatinib Sprycel 57 thyroglobulin 57 hypercholesterolemic 57 interferon alfa 2a 57 mcg albinterferon alfa 2b 57 interferon alfa 57 alanine aminotransferase 57 multivariate Cox 57 HCV replicon 57 microgram kg 57 humoral antibody 57 MALT lymphoma 57 CYP#C# [002] 57 confidence interval CI 57 perioperatively 57 karyotypes 57 hepatic enzymes 57 p# mitogen activated 57 evaluable patients 57 kDa protein 57 PTPN# 57 del 5q MDS 57 haematological 57 astrocytomas 57 abnormal p# biomarker 57 naïve HCV 57 biliary tract cancer 57 CIMZIA TM 57 progesterone receptor PR 57 lamivudine resistant 57 BCR ABL mutations 57 median survivals 57 mutant p# 57 antibody titers 57 hematological parameters 57 p# biomarker 57 cathepsins 57 serum aminotransferase levels 57 generalized edema 57 candidemia 57 colorectal liver metastases 57 cutaneous T 57 immunomodulatory properties 57 clinicopathological 57 Kinoid 57 deoxy 57 BMPR2 57 renal carcinoma 57 null mice 57 Parathyroid Hormone 57 liver metastasis 57 EGF receptor 57 piperacillin tazobactam 57 tumor shrinkage 57 DAPT 57 Papillary 57 taxane resistant 57 EGFr expressing mCRC 57 CYP#A# [002] 57 B7 H3 57 methicillin sensitive 57 epoetin alpha 57 EGFR protein 57 myeloproliferative diseases 57 intratumoral injection 57 resectable 57 chemokine receptors 57 intramuscularly 57 soluble tumor necrosis 57 EGFR expressing mCRC 57 mg QD 57 intraperitoneally 57 malignant lymphoma 57 chemo radiotherapy 57 Multiple Myeloma MM 57 glioblastoma cells 57 cTnI 57 cis retinoic acid 57 LPS induced 57 HLA DQ2 57 mcg BID 57 elevated transaminases 57 apolipoprotein E4 57 Relapsed Refractory Multiple Myeloma 57 Relapsed Refractory 57 TTF Therapy 57 papillary thyroid carcinoma 57 SPRYCEL ® 57 neutropenia dehydration dyspnea 57 CLA supplementation 57 Patients Receiving 57 HCV genotypes 57 NNRTI resistance 57 flutamide 57 pomalidomide 57 adjuvant cisplatin 57 CDH1 57 lymph node metastases 57 Pralatrexate 57 histologically proven 57 Overexpression 57 endometrioid 57 gastric carcinogenesis 57 Histologically 57 S aureus 57 null responder 57 IL 1ß 57 Trichophyton rubrum 57 LymphoStat B belimumab 57 leucopenia 57 leukemia ALL 57 CDKN2A 57 brain lesions 57 leukemia lymphomas 57 recovery CRp 57 dyskeratosis congenita 57 serum calcium levels 57 malignant fibrous histiocytoma 57 triiodothyronine 57 PEGylated Fab fragment 57 biologic DMARD 57 E. faecalis 57 acid phosphatase PAP 57 imipenem 57 Escherichia coli Klebsiella pneumoniae 57 Intravenous immunoglobulin 57 perineural invasion 57 Squamous 57 lenalidomide dexamethasone 57 SPINK1 57 acute myelogenous leukemia AML 57 LRP5 57 IgG4 57 achieved PASI 57 posttransplant 57 histologic 57 BALB c mice 57 Chronic Lymphocytic Leukemia CLL 57 MDR1 57 Subgroup analysis 57 radiochemotherapy 57 FOLFIRI 57 Teriflunomide 57 nonmyeloablative 57 human chorionic gonadotropin hCG 57 FasL 57 lymphoma subtypes 57 invasive lobular carcinoma 57 Median survival 57 Cell Lymphoma 57 uM 57 surgically resectable 57 splenic 57 #S rRNA gene 57 irinotecan cisplatin 57 heterozygous 57 glioma tumors 57 relapsed acute lymphoblastic 57 thrombocytopenic patients 57 immunomodulatory therapy 57 androgen ablation 57 pancreatic carcinoma 57 molecule epidermal 57 μg kg 57 neurologic progression 57 Flt3 57 coagulation parameters 57 treatment naive genotype 57 transplantation HCT 57 polyglutamate 57 HER2 positive cancers 57 GG genotype 57 CREBBP 57 glucuronide 57 aneuploid 57 BRAF mutation 57 Allogeneic 57 PSA nadir 57 extracapsular extension 57 polycythemia vera essential thrombocythemia 57 T#I mutant 57 Leucovorin 57 NPM1 mutations 57 EGFr expressing metastatic colorectal 57 CDK4 57 airway hyperresponsiveness 57 metastatic lesion 57 efaproxiral 57 microcephalin 57 CYP#C# * 57 intracranial hemorrhage ICH 57 Rate ORR 57 Cutaneous T 57 mammary tumors 57 Vidaza azacitidine 57 VEGFR1 57 bronchial epithelial cells 57 SGPT 57 herpesviruses 57 alkaline phosphatase 57 nilotinib Tasigna ® 57 GISTs 57 myocardial infarction ventricular fibrillation 57 relapsed ALL 57 cyclin E 57 HER2 positive metastatic breast 57 conventional DMARDs 57 PREZISTA r arm 57 #mg/day [001] 57 denileukin diftitox 57 cisplatin vinorelbine 57 Plasma concentrations 57 Omacetaxine 57 fulminant hepatic failure 57 mapatumumab 57 administered subcutaneously 57 myeloid 57 erythroid 57 log# copies mL 57 tenecteplase 57 adjunctive placebo 57 ribavirin therapy 57 MTHFR 57 neuroblastoma tumors 57 radiotherapy RT 57 ovarian carcinomas 57 malignant neoplasm 57 atypical hyperplasia 57 myeloid metaplasia 57 docetaxel prednisone 57 receiving INTRON 57 IGFBP 57 Hormone Refractory Prostate Cancer 57 pegylated interferon alfa 2b 57 III EGFRvIII 57 allogeneic SCT 57 methicillin susceptible Staphylococcus aureus 57 interferon γ 57 heparanase 57 precancerous tissues 57 tissue transglutaminase 57 mesotheliomas 57 serum antibody 57 cytochrome P 57 cytogenetic abnormalities 57 alkylating agents 57 ZOLINZA 57 Th1 56 mg m² 56 novel VDA molecule 56 atopic asthma 56 preintervention 56 gene expression patterns 56 myeloproliferative 56 TIMP 56 FOLFOX4 alone 56 temozolomide Temodar 56 fludarabine 56 indolent follicular non 56 Pegylated 56 accumulate preferentially 56 MAGE A3 ASCI 56 VKORC1 56 neoplasias 56 V#E 56 seminal vesicle invasion 56 histiocytes 56 gastric adenocarcinoma 56 cytokine Interleukin 56 adenylate cyclase 56 cEVR 56 ALT elevation 56 vincristine doxorubicin 56 thrombocytosis 56 Fludara 56 PEGPH#